

AZD-1222

S

Tinnitus and acute cochleopathy: case report

A 37-year-old man developed tinnitus and acute cochleopathy following first dose of the AZD-1222 for immunisation against COVID-19.

The man, who had glaucoma, had been treated with latanoprost and brimonidine eyedrops. On 30 April 2021, he received his first dose of AZD-1222 [manufactured by AstraZeneca; *route and dosage not stated*] at 11 am. However, he developed intermittent, right ear, high-pitch tinnitus from 4pm on 30 April 2021 with tinnitus handicap inventory (THI) score of 28. At midnight, he developed a high fever with chills along with myalgia. He received paracetamol [acetaminophen] with a poor response. Thus, he was admitted to the emergency department. Further, his tinnitus progressed to continuous high-pitch tinnitus and disturbed the normal hearing. Additionally, he developed low-pitch right ear tinnitus intermittently. Moreover, the THI score increased to 46. The audiometry test at 1 pm on 01 May 2021 revealed normal findings in the PTA; however, a high short increment sensitivity index was noted. He was diagnosed with acute inflammatory cochleopathy. His tinnitus and cochleopathy were attributed to AZD-1222.

The man was treated with dexamethasone and prednisolone. Following this, his fever and myalgia subsided promptly. Also, the right ear high-pitch and low-pitch tinnitus resolved completely on 03 May 2021. The subsequent audiometry showed the recovery by 5pm with the THI score returning to 0.

Tseng P-T, et al. The reversible tinnitus and cochleopathy followed first-dose AstraZeneca COVID-19 vaccination. *QJM - An International Journal of Medicine* 114: 663-664, No. 9, Sep 2021. Available from: URL: <http://qjmed.oxfordjournals.org/>

803654034